Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $17.63 and traded as high as $18.74. Theravance Biopharma shares last traded at $18.15, with a volume of 548,170 shares traded.

Analyst Ratings Changes

Several analysts have commented on the stock. Zacks Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Wall Street Zen cut shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday. Oppenheimer assumed coverage on shares of Theravance Biopharma in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 target price for the company. HC Wainwright increased their price target on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Finally, BTIG Research boosted their price objective on Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, November 26th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Price Performance

The stock has a market capitalization of $919.66 million, a PE ratio of 31.84 and a beta of 0.14. The stock’s fifty day moving average is $17.63 and its 200-day moving average is $14.43.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The business had revenue of $19.99 million during the quarter, compared to the consensus estimate of $19.89 million. On average, analysts forecast that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total transaction of $582,506.25. Following the transaction, the senior vice president owned 277,695 shares in the company, valued at approximately $5,206,781.25. This represents a 10.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock valued at $32,289,000 after buying an additional 54,152 shares in the last quarter. Park West Asset Management LLC raised its position in Theravance Biopharma by 0.6% during the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company’s stock worth $16,112,000 after acquiring an additional 11,256 shares during the period. Geode Capital Management LLC raised its position in Theravance Biopharma by 0.4% during the second quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock worth $9,863,000 after acquiring an additional 3,416 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Theravance Biopharma by 6.2% during the third quarter. Dimensional Fund Advisors LP now owns 766,704 shares of the biopharmaceutical company’s stock valued at $11,193,000 after purchasing an additional 44,634 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Theravance Biopharma in the third quarter valued at about $10,611,000. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.